Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces that the lastest preclinical data on its AdoXLong platform will be presented as a poster at the ObesityWeek 2026, taking place in Washington, USA, from November 14 17, 2026.
Poster Details:
Title: AdoXLong: A Long-Acting Peptide Platform Enabling Once-Monthly Administration of Incretins
Poster Presentation: Saturday, November 14, 2026, 7:30 8:30 pm EST (Washington, USA)
Session: Gut Peptides, Appetite Signaling Novel Therapeutics
Presenter: Martin Gaudier, PhD
About AdoXLong
Adocia has developed a new platform, AdoXLong, to address a critical challenge in diabetes and obesity treatments based on GLP-1 agonists, amylin, or other metabolic peptides: extend the duration of action of products currently administered weekly to reach a monthly injection. Beyond patient comfort it aims to provide, a monthly dosage form is intended to reduce the high discontinuation rate for these treatments observed within the first year, thereby enabling patients to fully benefit from the long-term metabolic effects of these therapies, which are lost when treatment is discontinued.
AdoXLong technology, for which Adocia has filed a patent application in November 2025, is a long-acting peptide platform composed of a biocompatible polymer chemically linked to the peptides without modifying their mechanisms of action. The technology is designed to offer a long circulating peptide over at least one month. The technology can be applied to a variety of peptides such as GLP-1, GIP, amylin, or dual/triple agonists including semaglutide, tirzepatide, cagrilintide with the possibility to combine these modified peptides with each other.
The patent application is expected to provide worldwide protection until 2046, if granted. The peptides using the technology would also benefit from reinforced intellectual property with an extension until 2046. The technology is applicable to both innovative and biosimilar peptides, including semaglutide, which will become off-patent starting in 2026 in certain territories.
Positive preliminary in vitro results have also been obtained with AdoXL Retatrutide, further validating the platform nature of AdoXLong. Adocia intends to continue developing its AdoXLong platform to advance toward clinical development.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone for the stabilization and enhancement of peptide formulations and combinations; 2) AdoXLong, a long-acting peptide platform; 3) AdOral, an oral peptide delivery technology; and 4) AdoShell, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation.
Adocia holds more than 25 patent families. Based in Lyon, the Company has about 80 employees. Adocia is listed on the regulated market of Euronext Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia, its business and the markets in which Adocia operates. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risk. The main risks faced by the Company are set out in Adocia's universal registration document filed with the French Autorité des marchés financiers on April 29, 2026, as updated in the Company's 2026 half-year financial report, published on September 25, 2026. Both documents are available free of charge on Adocia's website (www.adocia.com). Investor's attention is drawn in particular to the risks and uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or a solicitation of an offer to buy or subscribe for, Adocia shares in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261109907087/en/
Contacts:
Adocia
Olivier Soula
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com
Maarc
Adocia Press Investor Relations
Bruno Arabian
Yasmine Duval
Marie Arnoux
adocia-actionnaires@maarc.fr
+ 33 (0)6 87 88 47 26
